BRPI0818865A2 - Anticorpos monoclonais contra proteína c ativada. - Google Patents

Anticorpos monoclonais contra proteína c ativada.

Info

Publication number: BRPI0818865A2
Authority: BR; Brazil
Prior art keywords: monoclonal antibodies; antibodies against; activated protein; against activated; protein
Prior art date: 2007-10-26

Application number

Other languages

English (en)

Inventor

Jun Xu

Charles Esmon

Original Assignee

Oklahoma Med Res Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-26

Filing date

2008-10-24

Publication date

2015-05-05

2008-10-24 Application filed by Oklahoma Med Res Found filed Critical Oklahoma Med Res Found

2015-05-05 Publication of BRPI0818865A2 publication Critical patent/BRPI0818865A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Oncology (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)

BRPI0818865 2007-10-26 2008-10-24 Anticorpos monoclonais contra proteína c ativada. BRPI0818865A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US98309207P	2007-10-26	2007-10-26
PCT/US2008/081110 WO2009055669A2 (en)	2007-10-26	2008-10-24	Monoclonal antibodies against activated and unactivated protein c

Publications (1)

Publication Number	Publication Date
BRPI0818865A2 true BRPI0818865A2 (pt)	2015-05-05

Family

ID=40289112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0818865 BRPI0818865A2 (pt)	2007-10-26	2008-10-24	Anticorpos monoclonais contra proteína c ativada.

Country Status (13)

Country	Link
US (3)	US8153766B2 (pt)
EP (1)	EP2205638B1 (pt)
JP (3)	JP2011500843A (pt)
KR (2)	KR20150092358A (pt)
CN (3)	CN105153308A (pt)
AU (1)	AU2008316661B2 (pt)
BR (1)	BRPI0818865A2 (pt)
CA (1)	CA2703738C (pt)
IL (2)	IL205284A (pt)
MX (1)	MX2010004615A (pt)
RU (2)	RU2539729C2 (pt)
WO (1)	WO2009055669A2 (pt)
ZA (1)	ZA201105704B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9801362B2 (en) *	2012-03-16	2017-10-31	Regeneron Pharmaceuticals, Inc.	Non-human animals expressing pH-sensitive immunoglobulin sequences
CN104936618A (zh)	2012-11-29	2015-09-23	拜尔健康护理有限责任公司	针对活化蛋白c的人源化单克隆抗体及其用途
MX2015006424A (es) *	2012-11-29	2015-08-14	Bayer Healthcare Llc	Anticuerpos monoclonales contra una proteina activada c (apc).
TWI673063B (zh) *	2013-09-20	2019-10-01	日商中外製藥股份有限公司	抗蛋白ｃ抗體之出血性疾病的治療
GB201322091D0 (en)	2013-12-13	2014-01-29	Cambridge Entpr Ltd	Modified serpins for the treatment of bleeding disorders
WO2015179435A1 (en)	2014-05-19	2015-11-26	Bayer Healthcare Llc	Optimized humanized monoclonal antibodies against activated protein c and uses thereof
US11077187B2 (en) *	2015-11-17	2021-08-03	Oklahoma Medical Research Foundation	Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
EP3559035A1 (en)	2016-12-21	2019-10-30	TeneoBio, Inc.	Anti-bcma heavy chain-only antibodies
CN110891971B (zh)	2017-06-20	2024-01-12	特尼奥生物股份有限公司	仅有重链的抗bcma抗体
WO2019009407A1 (ja) *	2017-07-07	2019-01-10	第一三共株式会社	抗プロテインｃ抗体
US11447546B2 (en)	2017-07-20	2022-09-20	Nbe-Therapeutics Ag	Human antibodies binding to ROR2
EP3682247B1 (en) *	2017-09-13	2022-02-09	B.R.A.H.M.S GmbH	Proadrenomedullin as a marker for abnormal platelet levels
WO2020051277A1 (en) *	2018-09-06	2020-03-12	Board Of Regents, The University Of Texas System	Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr)
EP3867645B1 (en) *	2018-10-18	2024-06-05	Oklahoma Medical Research Foundation	Biomarkers for a systemic lupus erythematosus (sle) disease activity immune index that characterizes disease activity
CN109897108B (zh) *	2019-03-11	2021-04-02	上海恒赛生物科技有限公司	抗人内皮蛋白c受体的羊驼单域抗体及应用
EP3871689A1 (en)	2020-02-26	2021-09-01	sphingotec GmbH	Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
CN115611986B (zh) *	2021-07-13	2025-08-12	上海莱士血液制品股份有限公司	针对人活化蛋白c的单克隆抗体及其制备和应用
KR20240152428A (ko) *	2022-03-04	2024-10-21	주식회사 코애귤런트테라퓨틱스	활성화된 단백질 c에 대한 인간 항체 및 이의 용도
CN119136834A (zh) *	2022-03-04	2024-12-13	凝血剂治疗公司	针对活化蛋白c的骆驼科动物抗体及其用途
CN118370814A (zh) *	2023-01-20	2024-07-23	上海莱士血液制品股份有限公司	一种抗aPC单克隆抗体的制剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5202253A (en) *	1988-12-30	1993-04-13	Oklahoma Medical Research Foundation	Monoclonal antibody specific for protein C and antibody purification method
US7247453B1 (en) *	1988-12-30	2007-07-24	Oklahoma Medical Research Foundation	Calcium binding recombinant antibody against protein C
US5279956A (en)	1991-06-24	1994-01-18	The Scripps Research Institute	Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
US5695993A (en)	1994-08-12	1997-12-09	Oklahoma Medical Research Foundation	Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US6953568B1 (en)	1998-08-25	2005-10-11	Oklahoma Medical Research Foundation	Targeting of molecules to large vessel endothelium using EPCR
DE60141844D1 (de) *	2000-10-02	2010-05-27	Oklahoma Med Res Found	Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
US7423128B2 (en)	2004-11-03	2008-09-09	Amgen Fremont Inc.	Anti-properdin antibodies, and methods for making and using same

2008
- 2008-10-24 BR BRPI0818865 patent/BRPI0818865A2/pt active Search and Examination
- 2008-10-24 CA CA2703738A patent/CA2703738C/en active Active
- 2008-10-24 RU RU2010121148/10A patent/RU2539729C2/ru active
- 2008-10-24 KR KR1020157020430A patent/KR20150092358A/ko not_active Ceased
- 2008-10-24 WO PCT/US2008/081110 patent/WO2009055669A2/en not_active Ceased
- 2008-10-24 KR KR1020107011548A patent/KR101856210B1/ko active Active
- 2008-10-24 CN CN201510462991.XA patent/CN105153308A/zh active Pending
- 2008-10-24 EP EP08841295.2A patent/EP2205638B1/en active Active
- 2008-10-24 CN CN2013101082220A patent/CN103232541A/zh active Pending
- 2008-10-24 US US12/257,706 patent/US8153766B2/en active Active
- 2008-10-24 AU AU2008316661A patent/AU2008316661B2/en active Active
- 2008-10-24 CN CN2008801210245A patent/CN101918453A/zh active Pending
- 2008-10-24 JP JP2010531275A patent/JP2011500843A/ja not_active Withdrawn
- 2008-10-24 MX MX2010004615A patent/MX2010004615A/es active IP Right Grant
2010
- 2010-04-22 IL IL205284A patent/IL205284A/en active IP Right Grant
2011
- 2011-08-03 ZA ZA2011/05704A patent/ZA201105704B/en unknown
- 2011-11-29 US US13/306,301 patent/US9127072B2/en active Active
2012
- 2012-06-24 IL IL220622A patent/IL220622A0/en unknown
- 2012-10-26 JP JP2012236531A patent/JP2013049694A/ja active Pending
- 2012-11-27 RU RU2012150953/10A patent/RU2012150953A/ru not_active Application Discontinuation
2014
- 2014-07-02 JP JP2014136566A patent/JP6117741B2/ja active Active
2015
- 2015-06-09 US US14/734,055 patent/US20150344588A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL220622A0 (en)	2012-08-30
US8153766B2 (en)	2012-04-10
AU2008316661B2 (en)	2013-05-23
EP2205638A2 (en)	2010-07-14
US20090110683A1 (en)	2009-04-30
US20120164150A1 (en)	2012-06-28
CA2703738C (en)	2018-02-27
KR20150092358A (ko)	2015-08-12
JP2013049694A (ja)	2013-03-14
AU2008316661A1 (en)	2009-04-30
KR20100116166A (ko)	2010-10-29
KR101856210B1 (ko)	2018-05-09
JP2014237651A (ja)	2014-12-18
CA2703738A1 (en)	2009-04-30
EP2205638B1 (en)	2017-03-01
US20150344588A1 (en)	2015-12-03
ZA201105704B (en)	2014-05-28
US9127072B2 (en)	2015-09-08
CN101918453A (zh)	2010-12-15
RU2012150953A (ru)	2014-06-10
JP6117741B2 (ja)	2017-04-19
RU2010121148A (ru)	2011-12-10
WO2009055669A2 (en)	2009-04-30
JP2011500843A (ja)	2011-01-06
IL205284A0 (en)	2010-12-30
WO2009055669A3 (en)	2009-09-03
MX2010004615A (es)	2010-07-06
CN105153308A (zh)	2015-12-16
IL205284A (en)	2014-06-30
CN103232541A (zh)	2013-08-07
RU2539729C2 (ru)	2015-01-27

Publication	Publication Date	Title
HUS2100038I1 (hu)	2021-10-28	Anti-CD20 antitest készítmények
CY2019004I1 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0807991A2 (pt)	2014-06-17	Anticorpos anti-il-23r elaborados.
BRPI0720218A2 (pt)	2013-12-24	Anticorpos monoclonais contra angptl3
CY2016030I1 (el)	2016-12-14	Αντισωματα εναντι της il-17
BRPI0811907A2 (pt)	2014-11-18	Anticorpos monoclonais contra claudina-18 para tratamento de câncer.
LTC2358756I2 (lt)	2022-04-25	Žmogaus antikūnai, pasižymintys dideliu giminingumu pcsk9
NO344963B1 (no)	2020-08-03	Humanisert antistoff
PT1850873T (pt)	2019-02-19	Anticorpos contra tgfbeta
DK2066695T3 (da)	2013-06-10	Anti-myostatin-antistoffer
BRPI0819210A2 (pt)	2015-06-23	Anticorpos de proteína g anti-rsv
DK2225280T3 (da)	2014-05-26	Bivalente, bispecifikke antistoffer
BRPI0821405A2 (pt)	2015-06-16	Anticorpos biespecíficos, bivalentes
BRPI0821375A2 (pt)	2015-06-16	Anticorpos biespecíficos, bivalentes
DK2059533T3 (da)	2013-02-25	Multispecifikke antistoffer
BRPI0907532A2 (pt)	2015-07-28	Anticorpos anti-c5ar humanizados
DK2292663T3 (da)	2013-11-04	Antagonistiske human-let-specifikke, humane monoklonale antistoffer
FI20075278A0 (fi)	2007-04-20	Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
BRPI0809677A2 (pt)	2014-10-07	Anticorpos anti-ige
BRPI0918947A2 (pt)	2015-12-01	proteína de fusão de anticorpo
BRPI0819165A2 (pt)	2015-06-23	Anticorpos anti-vegf
HRP20150176T1 (xx)	2015-03-27	Protutijela protiv miostatina
LT3421498T (lt)	2022-03-10	Monokloniniai antikūnai prieš klaudiną-18, skirti vėžio gydymui
NL1027975A1 (nl)	2005-07-12	Antilichamen tegen MAdCAM.
PL3059246T3 (pl)	2018-11-30	Zmodyfikowany region stały przeciwciała

Legal Events

Date	Code	Title	Description
2015-09-22	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 3A ANUIDADE
2016-01-12	B08H	Application fees: decision cancelled [chapter 8.8 patent gazette]	Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2333 DE 22/09/2015
2016-01-19	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 4A ANUIDADE
2016-04-12	B08G	Application fees: restoration [chapter 8.7 patent gazette]
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2017-11-07	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 9A ANUIDADE.
2018-03-13	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
2018-05-08	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]